nach oben

Molecular Diagnosis & Therapy

Erschienen in:

01.10.2017 | Review Article

Current and Emerging Applications of Droplet Digital PCR in Oncology

verfasst von: Susana Olmedillas-López, Mariano García-Arranz, Damián García-Olmo

Erschienen in: Molecular Diagnosis & Therapy | Ausgabe 5/2017

Einloggen, um Zugang zu erhalten

Abstract

The clinical management of cancer has evolved in recent years towards more personalized strategies that require a comprehensive knowledge of the complex molecular features involved in tumor growth and evolution, and the development of drug resistance mechanisms leading to disease progression. Droplet digital PCR (ddPCR) has become one of the most accurate and reliable tools for the examination of genetic alterations in a wide variety of cancers because of its high sensitivity and specificity. ddPCR is currently being applied for absolute allele quantification, rare mutation detection, analysis of copy number variations, DNA methylation, and gene rearrangements in different kinds of clinical samples. This methodology has proven useful for the evaluation of archival tumor tissues, where poor DNA quality and limited sample availability are major obstacles for standard methods, providing less subjective and more automated quantitative results. However, most applications of ddPCR in cancer are focused on liquid biopsies (including cell-free DNA as well as circulating tumor cells) because these represent non-invasive alternatives to tissue biopsies that can more accurately reflect intratumoral heterogeneity and track the dynamic changes in tumor burden that occur in response to treatment at different times during follow-up. A broad spectrum of molecular markers have been interrogated in blood using ddPCR for diagnostic, predictive, and monitoring purposes in various malignancies. Emerging alternative approaches using other body fluids such as cerebrospinal fluid and urine are also currently being developed. This article aims to give a complete overview of ddPCR applications for molecular screening in oncology.

Vogelstein B, Papadopoulos N, Velculescu VE, Zhou S, Diaz LA, Kinzler KW. Cancer genome landscapes. Science. 2013;339(6127):1546–58.PubMedPubMedCentralCrossRef

Sforza V, Martinelli E, Ciardiello F, Gambardella V, Napolitano S, Martini G, et al. Mechanisms of resistance to anti-epidermal growth factor receptor inhibitors in metastatic colorectal cancer. World J Gastroenterol. 2016;22(28):6345–61.PubMedPubMedCentralCrossRef

Heitzer E, Ulz P, Geigl JB. Circulating tumor DNA as a liquid biopsy for cancer. Clin Chem. 2015;61(1):112–23.PubMedCrossRef

Hindson BJ, Ness KD, Masquelier DA, Belgrader P, Heredia NJ, Makarewicz AJ, et al. High-throughput droplet digital PCR system for absolute quantitation of DNA copy number. Anal Chem. 2011;83(22):8604–10.PubMedPubMedCentralCrossRef

Nadauld L, Regan JF, Miotke L, Pai RK, Longacre TA, Kwok SS, et al. Quantitative and sensitive detection of cancer genome amplifications from formalin fixed paraffin embedded tumors with droplet digital PCR. Transl Med (Sunnyvale). 2012;2(2). doi:10.4172/2161-1025.1000107.

Whale AS, Huggett JF, Cowen S, Speirs V, Shaw J, Ellison S, et al. Comparison of microfluidic digital PCR and conventional quantitative PCR for measuring copy number variation. Nucleic Acids Res. 2012;40(11):e82.PubMedPubMedCentralCrossRef

Hindson CM, Chevillet JR, Briggs HA, Gallichotte EN, Ruf IK, Hindson BJ, et al. Absolute quantification by droplet digital PCR versus analog real-time PCR. Nat Methods. 2013;10(10):1003–5.PubMedPubMedCentralCrossRef

Fontanelli G, Baratè C, Ciabatti E, Guerrini F, Grassi S, Del Re M, et al. Real-time PCR and droplet digital PCR: two techniques for detection of the JAK2(V617F) mutation in Philadelphia-negative chronic myeloproliferative neoplasms. Int J Lab Hematol. 2015;37(6):766–73.PubMedCrossRef

Morley AA. Digital PCR: a brief history. Biomol Detect Quantif. 2014;1(1):1–2.PubMedPubMedCentralCrossRef

10.

Jeffreys AJ, Neumann R, Wilson V. Repeat unit sequence variation in minisatellites: a novel source of DNA polymorphism for studying variation and mutation by single molecule analysis. Cell. 1990;60(3):473–85.PubMedCrossRef

11.

Ruano G, Kidd KK, Stephens JC. Haplotype of multiple polymorphisms resolved by enzymatic amplification of single DNA molecules. Proc Natl Acad Sci USA. 1990;87(16):6296–300.PubMedPubMedCentralCrossRef

12.

Simmonds P, Balfe P, Peutherer JF, Ludlam CA, Bishop JO, Brown AJ. Human immunodeficiency virus-infected individuals contain provirus in small numbers of peripheral mononuclear cells and at low copy numbers. J Virol. 1990;64(2):864–72.PubMedPubMedCentral

13.

Brisco MJ, Condon J, Sykes PJ, Neoh SH, Morley AA. Detection and quantitation of neoplastic cells in acute lymphoblastic leukaemia, by use of the polymerase chain reaction. Br J Haematol. 1991;79(2):211–7.PubMedCrossRef

14.

Huggett JF, Cowen S, Foy CA. Considerations for digital PCR as an accurate molecular diagnostic tool. Clin Chem. 2015;61(1):79–88.PubMedCrossRef

15.

Vogelstein B, Kinzler KW. Digital PCR. Proc Natl Acad Sci USA. 1999;96(16):9236–41.PubMedPubMedCentralCrossRef

16.

Dressman D, Yan H, Traverso G, Kinzler KW, Vogelstein B. Transforming single DNA molecules into fluorescent magnetic particles for detection and enumeration of genetic variations. Proc Natl Acad Sci USA. 2003;100(15):8817–22.PubMedPubMedCentralCrossRef

17.

Janku F, Angenendt P, Tsimberidou AM, Fu S, Naing A, Falchook GS, et al. Actionable mutations in plasma cell-free DNA in patients with advanced cancers referred for experimental targeted therapies. Oncotarget. 2015;6(14):12809–21.PubMedPubMedCentralCrossRef

18.

Higgins MJ, Jelovac D, Barnathan E, Blair B, Slater S, Powers P, et al. Detection of tumor PIK3CA status in metastatic breast cancer using peripheral blood. Clin Cancer Res. 2012;18(12):3462–9.PubMedPubMedCentralCrossRef

19.

Yoo C, Ryu MH, Na YS, Ryoo BY, Park SR, Kang YK. Analysis of serum protein biomarkers, circulating tumor DNA, and dovitinib activity in patients with tyrosine kinase inhibitor-refractory gastrointestinal stromal tumors. Ann Oncol. 2014;25(11):2272–7.PubMedCrossRef

20.

Taniguchi K, Uchida J, Nishino K, Kumagai T, Okuyama T, Okami J, et al. Quantitative detection of EGFR mutations in circulating tumor DNA derived from lung adenocarcinomas. Clin Cancer Res. 2011;17(24):7808–15.PubMedCrossRef

21.

Karlovich C, Goldman JW, Sun JM, Mann E, Sequist LV, Konopa K, et al. Assessment of EGFR mutation status in matched plasma and tumor tissue of NSCLC patients from a phase I study of rociletinib (CO-1686). Clin Cancer Res. 2016;22(10):2386–95.PubMedCrossRef

22.

Oxnard GR, Thress KS, Alden RS, Lawrance R, Paweletz CP, Cantarini M, et al. Association between plasma genotyping and outcomes of treatment with osimertinib (AZD9291) in advanced non-small-cell lung cancer. J Clin Oncol. 2016;34(28):3375–82.PubMedCrossRef

23.

Thress KS, Brant R, Carr TH, Dearden S, Jenkins S, Brown H, et al. EGFR mutation detection in ctDNA from NSCLC patient plasma: a cross-platform comparison of leading technologies to support the clinical development of AZD9291. Lung Cancer. 2015;90(3):509–15.PubMedCrossRef

24.

Bokemeyer C, Köhne CH, Ciardiello F, Lenz HJ, Heinemann V, Klinkhardt U, et al. FOLFOX4 plus cetuximab treatment and RAS mutations in colorectal cancer. Eur J Cancer. 2015;51(10):1243–52.PubMedCrossRef

25.

Tabernero J, Lenz HJ, Siena S, Sobrero A, Falcone A, Ychou M, et al. Analysis of circulating DNA and protein biomarkers to predict the clinical activity of regorafenib and assess prognosis in patients with metastatic colorectal cancer: a retrospective, exploratory analysis of the CORRECT trial. Lancet Oncol. 2015;16(8):937–48.PubMedCrossRef

26.

Toledo RA, Cubillo A, Vega E, Garralda E, Alvarez R, de la Varga LU, et al. Clinical validation of prospective liquid biopsy monitoring in patients with wild-type RAS metastatic colorectal cancer treated with FOLFIRI-cetuximab. Oncotarget. 2016. doi:10.18632/oncotarget.13311.

27.

Diehl F, Li M, Dressman D, He Y, Shen D, Szabo S, et al. Detection and quantification of mutations in the plasma of patients with colorectal tumors. Proc Natl Acad Sci USA. 2005;102(45):16368–73.PubMedPubMedCentralCrossRef

28.

Diehl F, Schmidt K, Durkee KH, Moore KJ, Goodman SN, Shuber AP, et al. Analysis of mutations in DNA isolated from plasma and stool of colorectal cancer patients. Gastroenterology. 2008;135(2):489–98.PubMedPubMedCentralCrossRef

29.

Azuara D, Ginesta MM, Gausachs M, Rodriguez-Moranta F, Fabregat J, Busquets J, et al. Nanofluidic digital PCR for KRAS mutation detection and quantification in gastrointestinal cancer. Clin Chem. 2012;58(9):1332–41.PubMedCrossRef

30.

Riediger AL, Dietz S, Schirmer U, Meister M, Heinzmann-Groth I, Schneider M, et al. Mutation analysis of circulating plasma DNA to determine response to EGFR tyrosine kinase inhibitor therapy of lung adenocarcinoma patients. Sci Rep. 2016;6:33505.PubMedPubMedCentralCrossRef

31.

Oxnard GR, Paweletz CP, Kuang Y, Mach SL, O’Connell A, Messineo MM, et al. Noninvasive detection of response and resistance in EGFR-mutant lung cancer using quantitative next-generation genotyping of cell-free plasma DNA. Clin Cancer Res. 2014;20(6):1698–705.PubMedPubMedCentralCrossRef

32.

Laurent-Puig P, Pekin D, Normand C, Kotsopoulos SK, Nizard P, Perez-Toralla K, et al. Clinical relevance of KRAS-mutated subclones detected with picodroplet digital PCR in advanced colorectal cancer treated with anti-EGFR therapy. Clin Cancer Res. 2015;21(5):1087–97.PubMedCrossRef

33.

Dong L, Meng Y, Sui Z, Wang J, Wu L, Fu B. Comparison of four digital PCR platforms for accurate quantification of DNA copy number of a certified plasmid DNA reference material. Sci Rep. 2015;5:13174.PubMedPubMedCentralCrossRef

34.

Tsao SC, Weiss J, Hudson C, Christophi C, Cebon J, Behren A, et al. Monitoring response to therapy in melanoma by quantifying circulating tumour DNA with droplet digital PCR for BRAF and NRAS mutations. Sci Rep. 2015;5:11198.PubMedCrossRef

35.

Drandi D, Kubiczkova-Besse L, Ferrero S, Dani N, Passera R, Mantoan B, et al. Minimal residual disease detection by droplet digital PCR in multiple myeloma, mantle cell lymphoma, and follicular lymphoma: a comparison with real-time PCR. J Mol Diagn. 2015;17(6):652–60.PubMedCrossRef

36.

Huggett JF, Foy CA, Benes V, Emslie K, Garson JA, Haynes R, et al. The digital MIQE guidelines: minimum information for publication of quantitative digital PCR experiments. Clin Chem. 2013;59(6):892–902.PubMedCrossRef

37.

Perkins G, Lu H, Garlan F, Taly V. Droplet-based digital PCR: application in cancer research. Adv Clin Chem. 2017;79:43–91.PubMedCrossRef

38.

Milbury CA, Zhong Q, Lin J, Williams M, Olson J, Link DR, et al. Determining lower limits of detection of digital PCR assays for cancer-related gene mutations. Biomol Detect Quantif. 2014;1(1):8–22.PubMedPubMedCentralCrossRef

39.

Cochran RL, Cravero K, Chu D, Erlanger B, Toro PV, Beaver JA, et al. Analysis of BRCA2 loss of heterozygosity in tumor tissue using droplet digital polymerase chain reaction. Hum Pathol. 2014;45(7):1546–50.PubMedPubMedCentralCrossRef

40.

Mazaika E, Homsy J. Digital droplet PCR: CNV analysis and other applications. Curr Protoc Hum Genet. 2014;82:7.24.1–24.13.CrossRef

41.

Belgrader P, Tanner SC, Regan JF, Koehler R, Hindson BJ, Brown AS. Droplet digital PCR measurement of HER2 copy number alteration in formalin-fixed paraffin-embedded breast carcinoma tissue. Clin Chem. 2013;59(6):991–4.PubMedCrossRef

42.

Heredia NJ, Belgrader P, Wang S, Koehler R, Regan J, Cosman AM, et al. Droplet digital™ PCR quantitation of HER2 expression in FFPE breast cancer samples. Methods. 2013;59(1):S20–3.PubMedCrossRef

43.

Kinugasa H, Nouso K, Tanaka T, Miyahara K, Morimoto Y, Dohi C, et al. Droplet digital PCR measurement of HER2 in patients with gastric cancer. Br J Cancer. 2015;112(10):1652–5.PubMedPubMedCentralCrossRef

44.

Zhu Y, Lu D, Lira ME, Xu Q, Du Y, Xiong J, et al. Droplet digital polymerase chain reaction detection of HER2 amplification in formalin fixed paraffin embedded breast and gastric carcinoma samples. Exp Mol Pathol. 2016;100(2):287–93.PubMedCrossRef

45.

Garcia-Murillas I, Lambros M, Turner NC. Determination of HER2 amplification status on tumour DNA by digital PCR. PLoS One. 2013;8(12):e83409.PubMedPubMedCentralCrossRef

46.

Otsuji K, Sasaki T, Tanaka A, Kunita A, Ikemura M, Matsusaka K, et al. Use of droplet digital PCR for quantitative and automatic analysis of the HER2 status in breast cancer patients. Breast Cancer Res Treat. 2017;162(1):11–8.PubMedCrossRef

47.

Meehan K, Clynick B, Mirzai B, Maslen P, Harvey JM, Erber WN. HER2 mRNA transcript quantitation in breast cancer. Clin Transl Oncol. 2017;19(5):606–15.

48.

Fina F, Barets D, Colin C, Bouvier C, Padovani L, Nanni-Metellus I, et al. Droplet digital PCR is a powerful technique to demonstrate frequent FGFR1 duplication in dysembryoplastic neuroepithelial tumors. Oncotarget. 2017;8(2):2104–13.

49.

Hughesman CB, Lu XJ, Liu KY, Zhu Y, Poh CF, Haynes C. A robust protocol for using multiplexed droplet digital PCR to quantify somatic copy number alterations in clinical tissue specimens. PLoS One. 2016;11(8):e0161274.PubMedPubMedCentralCrossRef

50.

Pender A, Garcia-Murillas I, Rana S, Cutts RJ, Kelly G, Fenwick K, et al. Efficient genotyping of KRAS mutant non-small cell lung cancer using a multiplexed droplet digital PCR approach. PLoS One. 2015;10(9):e0139074.PubMedPubMedCentralCrossRef

51.

Lira ME, Choi YL, Lim SM, Deng S, Huang D, Ozeck M, et al. A single-tube multiplexed assay for detecting ALK, ROS1, and RET fusions in lung cancer. J Mol Diagn. 2014;16(2):229–43.PubMedCrossRef

52.

Ayturk UM, Couto JA, Hann S, Mulliken JB, Williams KL, Huang AY, et al. Somatic activating mutations in GNAQ and GNA11 are associated with congenital hemangioma. Am J Hum Genet. 2016;98(4):789–95.PubMedPubMedCentralCrossRef

53.

Couto JA, Vivero MP, Kozakewich HP, Taghinia AH, Mulliken JB, Warman ML, et al. A somatic MAP3K3 mutation is associated with verrucous venous malformation. Am J Hum Genet. 2015;96(3):480–6.PubMedPubMedCentralCrossRef

54.

Alcaide M, Yu S, Bushell K, Fornika D, Nielsen JS, Nelson BH, et al. Multiplex droplet digital PCR quantification of recurrent somatic mutations in diffuse large B-cell and follicular lymphoma. Clin Chem. 2016;62(9):1238–47.PubMedCrossRef

55.

Bidshahri R, Attali D, Fakhfakh K, McNeil K, Karsan A, Won JR, et al. Quantitative detection and resolution of BRAF V600 status in colorectal cancer using droplet digital PCR and a novel wild-type negative assay. J Mol Diagn. 2016;18(2):190–204.PubMedCrossRef

56.

Watanabe M, Kawaguchi T, Isa S, Ando M, Tamiya A, Kubo A, et al. Ultra-sensitive detection of the pretreatment EGFR T790M mutation in non-small cell lung cancer patients with an EGFR-activating mutation using droplet digital PCR. Clin Cancer Res. 2015;21(15):3552–60.PubMedCrossRef

57.

Wang Q, Yang X, He Y, Ma Q, Lin L, Fu P, et al. Droplet digital PCR for absolute quantification of EML4-ALK gene rearrangement in lung adenocarcinoma. J Mol Diagn. 2015;17(5):515–20.PubMedCrossRef

58.

Lund HL, Hughesman CB, Fakhfakh K, McNeil K, Clemens S, Hocken K, et al. Initial diagnosis of ALK-positive non-small-cell lung cancer based on analysis of ALK status utilizing droplet digital PCR. Anal Chem. 2016;88(9):4879–85.PubMedCrossRef

59.

Beaver JA, Jelovac D, Balukrishna S, Cochran RL, Croessmann S, Zabransky DJ, et al. Detection of cancer DNA in plasma of patients with early-stage breast cancer. Clin Cancer Res. 2014;20(10):2643–50.PubMedPubMedCentralCrossRef

60.

Whale AS, Huggett JF, Tzonev S. Fundamentals of multiplexing with digital PCR. Biomol Detect Quantif. 2016;10:15–23.PubMedPubMedCentralCrossRef

61.

Jones M, Williams J, Gärtner K, Phillips R, Hurst J, Frater J. Low copy target detection by droplet digital PCR through application of a novel open access bioinformatic pipeline, ‘definetherain’. J Virol Methods. 2014;202:46–53.PubMedPubMedCentralCrossRef

62.

Dreo T, Pirc M, Ramšak Ž, Pavšič J, Milavec M, Zel J, et al. Optimising droplet digital PCR analysis approaches for detection and quantification of bacteria: a case study of fire blight and potato brown rot. Anal Bioanal Chem. 2014;406(26):6513–28.PubMedCrossRef

63.

Lievens A, Jacchia S, Kagkli D, Savini C, Querci M. Measuring digital PCR quality: performance parameters and their optimization. PLoS One. 2016;11(5):e0153317.PubMedPubMedCentralCrossRef

64.

Bettoni F, Masotti C, Habr-Gama A, Correa BR, Gama-Rodrigues J, Vianna MR, et al. Intratumoral genetic heterogeneity in rectal cancer: are single biopsies representative of the entirety of the tumor? Ann Surg. 2017;265(1):e4–6.

65.

Crowley E, Di Nicolantonio F, Loupakis F, Bardelli A. Liquid biopsy: monitoring cancer-genetics in the blood. Nat Rev Clin Oncol. 2013;10(8):472–84.PubMedCrossRef

66.

Diaz LA, Bardelli A. Liquid biopsies: genotyping circulating tumor DNA. J Clin Oncol. 2014;32(6):579–86.PubMedPubMedCentralCrossRef

67.

Yanagita M, Redig AJ, Paweletz CP, Dahlberg SE, O’Connell A, Feeney N, et al. A prospective evaluation of circulating tumor cells and cell-free DNA in EGFR-mutant non-small cell lung cancer patients treated with erlotinib on a phase II trial. Clin Cancer Res. 2016;22(24):6010–20.PubMedCrossRef

68.

Guibert N, Pradines A, Farella M, Casanova A, Gouin S, Keller L, et al. Monitoring KRAS mutations in circulating DNA and tumor cells using digital droplet PCR during treatment of KRAS-mutated lung adenocarcinoma. Lung Cancer. 2016;100:1–4.PubMedCrossRef

69.

Pereira E, Camacho-Vanegas O, Anand S, Sebra R, Catalina Camacho S, Garnar-Wortzel L, et al. Personalized circulating tumor DNA biomarkers dynamically predict treatment response and survival in gynecologic cancers. PLoS One. 2015;10(12):e0145754.PubMedPubMedCentralCrossRef

70.

Kim ST, Lira M, Deng S, Lee S, Park YS, Lim HY, et al. PIK3CA mutation detection in metastatic biliary cancer using cell-free DNA. Oncotarget. 2015;6(37):40026–35.PubMedPubMedCentralCrossRef

71.

Combaret V, Iacono I, Bellini A, Bréjon S, Bernard V, Marabelle A, et al. Detection of tumor ALK status in neuroblastoma patients using peripheral blood. Cancer Med. 2015;4(4):540–50.PubMedPubMedCentralCrossRef

72.

Del Re M, Tiseo M, Bordi P, D’Incecco A, Camerini A, Petrini I, et al. Contribution of KRAS mutations and c.2369C>T (p.T790M) EGFR to acquired resistance to EGFR-TKIs in EGFR mutant NSCLC: a study on circulating tumor DNA. Oncotarget. 2017;8(8):13611–9.

73.

Chia PL, Do H, Morey A, Mitchell P, Dobrovic A, John T. Temporal changes of EGFR mutations and T790M levels in tumour and plasma DNA following AZD9291 treatment. Lung Cancer. 2016;98:29–32.PubMedCrossRef

74.

Alegre E, Fusco JP, Restituto P, Salas-Benito D, Rodríguez-Ruiz ME, Andueza MP, et al. Total and mutated EGFR quantification in cell-free DNA from non-small cell lung cancer patients detects tumor heterogeneity and presents prognostic value. Tumour Biol. 2016;37(10):13687–94.PubMedCrossRef

75.

Zheng D, Ye X, Zhang MZ, Sun Y, Wang JY, Ni J, et al. Plasma EGFR T790M ctDNA status is associated with clinical outcome in advanced NSCLC patients with acquired EGFR-TKI resistance. Sci Rep. 2016;6:20913.PubMedPubMedCentralCrossRef

76.

Zhu G, Ye X, Dong Z, Lu YC, Sun Y, Liu Y, et al. Highly sensitive droplet digital PCR method for detection of EGFR-activating mutations in plasma cell-free DNA from patients with advanced non-small cell lung cancer. J Mol Diagn. 2015;17(3):265–72.PubMedCrossRef

77.

Takahama T, Sakai K, Takeda M, Azuma K, Hida T, Hirabayashi M, et al. Detection of the T790M mutation of EGFR in plasma of advanced non-small cell lung cancer patients with acquired resistance to tyrosine kinase inhibitors (West Japan oncology group 8014LTR study). Oncotarget. 2016;7(36):58492–9.PubMedPubMedCentralCrossRef

78.

Wei Z, Shah N, Deng C, Xiao X, Zhong T, Li X. Circulating DNA addresses cancer monitoring in non small cell lung cancer patients for detection and capturing the dynamic changes of the disease. Springerplus. 2016;5:531.PubMedPubMedCentralCrossRef

79.

Zhao J, Ye X, Xu Y, Chen M, Zhong W, Sun Y, et al. EGFR mutation status of paired cerebrospinal fluid and plasma samples in EGFR mutant non-small cell lung cancer with leptomeningeal metastases. Cancer Chemother Pharmacol. 2016;78(6):1305–10.PubMedCrossRef

80.

Zonta E, Garlan F, Pécuchet N, Perez-Toralla K, Caen O, Milbury C, et al. Multiplex detection of rare mutations by picoliter droplet based digital PCR: sensitivity and specificity considerations. PLoS One. 2016;11(7):e0159094.PubMedPubMedCentralCrossRef

81.

Seki Y, Fujiwara Y, Kohno T, Takai E, Sunami K, Goto Y, et al. Picoliter-droplet digital polymerase chain reaction-based analysis of cell-free plasma DNA to assess EGFR mutations in lung adenocarcinoma that confer resistance to tyrosine-kinase inhibitors. Oncologist. 2016;21(2):156–64.PubMedPubMedCentralCrossRef

82.

Ishii H, Azuma K, Sakai K, Kawahara A, Yamada K, Tokito T, et al. Digital PCR analysis of plasma cell-free DNA for non-invasive detection of drug resistance mechanisms in EGFR mutant NSCLC: correlation with paired tumor samples. Oncotarget. 2015;6(31):30850–8.PubMedPubMedCentralCrossRef

83.

Sacher AG, Paweletz C, Dahlberg SE, Alden RS, O’Connell A, Feeney N, et al. Prospective validation of rapid plasma genotyping for the detection of EGFR and KRAS mutations in advanced lung cancer. JAMA Oncol. 2016;2(8):1014–22.PubMedPubMedCentralCrossRef

84.

Lee JY, Qing X, Xiumin W, Yali B, Chi S, Bak SH, et al. Longitudinal monitoring of EGFR mutations in plasma predicts outcomes of NSCLC patients treated with EGFR TKIs: Korean Lung Cancer Consortium (KLCC-12-02). Oncotarget. 2016;7(6):6984–93.PubMedPubMedCentralCrossRef

85.

Yang X, Zhuo M, Ye X, Bai H, Wang Z, Sun Y, et al. Quantification of mutant alleles in circulating tumor DNA can predict survival in lung cancer. Oncotarget. 2016;7(15):20810–24.PubMedPubMedCentralCrossRef

86.

Zhang Y, Xu Y, Zhong W, Zhao J, Chen M, Zhang L, et al. Total DNA input is a crucial determinant of the sensitivity of plasma cell-free DNA EGFR mutation detection using droplet digital PCR. Oncotarget. 2017;8(4):5861–73.

87.

Huang A, Zhang X, Zhou SL, Cao Y, Huang XW, Fan J, et al. Detecting circulating tumor DNA in hepatocellular carcinoma patients using droplet digital PCR is feasible and reflects intratumoral heterogeneity. J Cancer. 2016;7(13):1907–14.PubMedPubMedCentralCrossRef

88.

Guttery DS, Page K, Hills A, Woodley L, Marchese SD, Rghebi B, et al. Noninvasive detection of activating estrogen receptor 1 (ESR1) mutations in estrogen receptor-positive metastatic breast cancer. Clin Chem. 2015;61(7):974–82.PubMedCrossRef

89.

Fribbens C, O’Leary B, Kilburn L, Hrebien S, Garcia-Murillas I, Beaney M, et al. Plasma ESR1 mutations and the treatment of estrogen receptor-positive advanced breast cancer. J Clin Oncol. 2016;34(25):2961–8.PubMedCrossRef

90.

Takeshita T, Yamamoto Y, Yamamoto-Ibusuki M, Inao T, Sueta A, Fujiwara S, et al. Clinical significance of monitoring ESR1 mutations in circulating cell-free DNA in estrogen receptor positive breast cancer patients. Oncotarget. 2016;7(22):32504–18.PubMedPubMedCentralCrossRef

91.

Wang P, Bahreini A, Gyanchandani R, Lucas PC, Hartmaier RJ, Watters RJ, et al. Sensitive detection of mono- and polyclonal ESR1 mutations in primary tumors, metastatic lesions, and cell-free DNA of breast cancer patients. Clin Cancer Res. 2016;22(5):1130–7.PubMedCrossRef

92.

Schiavon G, Hrebien S, Garcia-Murillas I, Cutts RJ, Pearson A, Tarazona N, et al. Analysis of ESR1 mutation in circulating tumor DNA demonstrates evolution during therapy for metastatic breast cancer. Sci Transl Med. 2015;7(313):313ra182.PubMedPubMedCentralCrossRef

93.

Clatot F, Perdrix A, Augusto L, Beaussire L, Delacour J, Calbrix C, et al. Kinetics, prognostic and predictive values of ESR1 circulating mutations in metastatic breast cancer patients progressing on aromatase inhibitor. Oncotarget. 2016;7(46):74448–59.PubMedPubMedCentral

94.

Takeshita T, Yamamoto Y, Yamamoto-Ibusuki M, Inao T, Sueta A, Fujiwara S, et al. Prognostic role of PIK3CA mutations of cell-free DNA in early-stage triple negative breast cancer. Cancer Sci. 2015;106(11):1582–9.PubMedPubMedCentralCrossRef

95.

García-Murillas I, Schiavon G, Weigelt B, Ng C, Hrebien S, Cutts RJ, et al. Mutation tracking in circulating tumor DNA predicts relapse in early breast cancer. Sci Transl Med. 2015;7(302):302ra133.PubMedCrossRef

96.

Sanmamed MF, Fernández-Landázuri S, Rodríguez C, Zárate R, Lozano MD, Zubiri L, et al. Quantitative cell-free circulating BRAFV600E mutation analysis by use of droplet digital PCR in the follow-up of patients with melanoma being treated with BRAF inhibitors. Clin Chem. 2015;61(1):297–304.PubMedCrossRef

97.

Chang GA, Tadepalli JS, Shao Y, Zhang Y, Weiss S, Robinson E, et al. Sensitivity of plasma BRAFmutant and NRASmutant cell-free DNA assays to detect metastatic melanoma in patients with low RECIST scores and non-RECIST disease progression. Mol Oncol. 2016;10(1):157–65.PubMedCrossRef

98.

Gray ES, Rizos H, Reid AL, Boyd SC, Pereira MR, Lo J, et al. Circulating tumor DNA to monitor treatment response and detect acquired resistance in patients with metastatic melanoma. Oncotarget. 2015;6(39):42008–18.PubMedPubMedCentralCrossRef

99.

Gevensleben H, Garcia-Murillas I, Graeser MK, Schiavon G, Osin P, Parton M, et al. Noninvasive detection of HER2 amplification with plasma DNA digital PCR. Clin Cancer Res. 2013;19(12):3276–84.PubMedCrossRef

100.

Olsson E, Winter C, George A, Chen Y, Howlin J, Tang MH, et al. Serial monitoring of circulating tumor DNA in patients with primary breast cancer for detection of occult metastatic disease. EMBO Mol Med. 2015;7(8):1034–47.PubMedPubMedCentralCrossRef

101.

Uehiro N, Sato F, Pu F, Tanaka S, Kawashima M, Kawaguchi K, et al. Circulating cell-free DNA-based epigenetic assay can detect early breast cancer. Breast Cancer Res. 2016;18(1):129.PubMedPubMedCentralCrossRef

102.

Hata T, Dal Molin M, Hong SM, Tamura K, Suenaga M, Yu J, et al. Predicting the grade of dysplasia of pancreatic cystic neoplasms using cyst fluid DNA methylation markers. Clin Cancer Res. 2017. doi:10.1158/1078-0432.CCR-16-2244

103.

Garrigou S, Perkins G, Garlan F, Normand C, Didelot A, Le Corre D, et al. A study of hypermethylated circulating tumor DNA as a universal colorectal cancer biomarker. Clin Chem. 2016;62(8):1129–39.PubMedCrossRef

104.

Taly V, Pekin D, Benhaim L, Kotsopoulos SK, Le Corre D, Li X, et al. Multiplex picodroplet digital PCR to detect KRAS mutations in circulating DNA from the plasma of colorectal cancer patients. Clin Chem. 2013;59(12):1722–31.PubMedCrossRef

105.

Janku F, Huang HJ, Fujii T, Shelton DN, Madwani K, Fu S, et al. Multiplex KRASG12/G13 mutation testing of unamplified cell-free DNA from the plasma of patients with advanced cancers using droplet digital polymerase chain reaction. Ann Oncol. 2017;28(3):642–50.

106.

Allenson K, Castillo J, San Lucas FA, Scelo G, Kim DU, Bernard V, et al. High prevalence of mutant KRAS in circulating exosome-derived DNA from early stage pancreatic cancer patients. Ann Oncol. 2017;28(4):741–7.

107.

Mitchell PS, Parkin RK, Kroh EM, Fritz BR, Wyman SK, Pogosova-Agadjanyan EL, et al. Circulating microRNAs as stable blood-based markers for cancer detection. Proc Natl Acad Sci USA. 2008;105(30):10513–8.PubMedPubMedCentralCrossRef

108.

Campomenosi P, Gini E, Noonan DM, Poli A, D’Antona P, Rotolo N, et al. A comparison between quantitative PCR and droplet digital PCR technologies for circulating microRNA quantification in human lung cancer. BMC Biotechnol. 2016;16(1):60.PubMedPubMedCentralCrossRef

109.

Mangolini A, Ferracin M, Zanzi MV, Saccenti E, Ebnaof SO, Poma VV, et al. Diagnostic and prognostic microRNAs in the serum of breast cancer patients measured by droplet digital PCR. Biomark Res. 2015;3:12.PubMedPubMedCentralCrossRef

110.

Ferracin M, Lupini L, Salamon I, Saccenti E, Zanzi MV, Rocchi A, et al. Absolute quantification of cell-free microRNAs in cancer patients. Oncotarget. 2015;6(16):14545–55.PubMedPubMedCentralCrossRef

111.

Del Re M, Biasco E, Crucitta S, Derosa L, Rofi E, Orlandini C, et al. The detection of androgen receptor splice variant 7 in plasma-derived exosomal RNA strongly predicts resistance to hormonal therapy in metastatic prostate cancer patients. Eur Urol. 2017;71(4):680–7.

112.

Chen WW, Balaj L, Liau LM, Samuels ML, Kotsopoulos SK, Maguire CA, et al. BEAMing and droplet digital PCR analysis of mutant IDH1 mRNA in glioma patient serum and cerebrospinal fluid extracellular vesicles. Mol Ther Nucleic Acids. 2013;2:e109.PubMedPubMedCentralCrossRef

113.

Denis JA, Patroni A, Guillerm E, Pépin D, Benali-Furet N, Wechsler J, et al. Droplet digital PCR of circulating tumor cells from colorectal cancer patients can predict KRAS mutations before surgery. Mol Oncol. 2016;10(8):1221–31.PubMedPubMedCentralCrossRef

114.

Yoo CE, Park JM, Moon HS, Joung JG, Son DS, Jeon HJ, et al. Vertical magnetic separation of circulating tumor cells for somatic genomic-alteration analysis in lung cancer patients. Sci Rep. 2016;6:37392.PubMedPubMedCentralCrossRef

115.

Reid AL, Freeman JB, Millward M, Ziman M, Gray ES. Detection of BRAF-V600E and V600K in melanoma circulating tumour cells by droplet digital PCR. Clin Biochem. 2015;48(15):999–1002.PubMedCrossRef

116.

Ma Y, Luk A, Young FP, Lynch D, Chua W, Balakrishnar B, et al. Droplet digital PCR based androgen receptor variant 7 (AR-V7) detection from prostate cancer patient blood biopsies. Int J Mol Sci. 2016;17(8). doi:10.3390/ijms17081264.

117.

Anelli L, Zagaria A, Coccaro N, Tota G, Minervini A, Casieri P, et al. Droplet digital PCR assay for quantifying of CALR mutant allelic burden in myeloproliferative neoplasms. Ann Hematol. 2016;95(9):1559–60.PubMedCrossRef

118.

Haslam K, Langabeer SE. Monitoring minimal residual disease in the myeloproliferative neoplasms: current applications and emerging approaches. Biomed Res Int. 2016;2016:7241591.PubMedPubMedCentralCrossRef

119.

Della Starza I, Nunes V, Cavalli M, De Novi LA, Ilari C, Apicella V, et al. Comparative analysis between RQ-PCR and digital-droplet-PCR of immunoglobulin/T-cell receptor gene rearrangements to monitor minimal residual disease in acute lymphoblastic leukaemia. Br J Haematol. 2016;174(4):541–9.PubMedCrossRef

120.

Guerrini F, Paolicchi M, Ghio F, Ciabatti E, Grassi S, Salehzadeh S, et al. The droplet digital PCR: a new valid molecular approach for the assessment of B-RAF V600E mutation in hairy cell leukemia. Front Pharmacol. 2016;7:363.PubMedPubMedCentralCrossRef

121.

Minervini A, Francesco Minervini C, Anelli L, Zagaria A, Casieri P, Coccaro N, et al. Droplet digital PCR analysis of NOTCH1 gene mutations in chronic lymphocytic leukemia. Oncotarget. 2016;7(52):86469–79.PubMedPubMedCentral

122.

Jennings LJ, George D, Czech J, Yu M, Joseph L. Detection and quantification of BCR-ABL1 fusion transcripts by droplet digital PCR. J Mol Diagn. 2014;16(2):174–9.PubMedCrossRef

123.

Albano F, Zagaria A, Anelli L, Coccaro N, Tota G, Brunetti C, et al. Absolute quantification of the pretreatment PML-RARA transcript defines the relapse risk in acute promyelocytic leukemia. Oncotarget. 2015;6(15):13269–77.PubMedPubMedCentralCrossRef

124.

Brambati C, Galbiati S, Xue E, Toffalori C, Crucitti L, Greco R, et al. Droplet digital polymerase chain reaction for DNMT3A and IDH1/2 mutations to improve early detection of acute myeloid leukemia relapse after allogeneic hematopoietic stem cell transplantation. Haematologica. 2016;101(4):e157–61.PubMedPubMedCentralCrossRef

125.

Pan W, Gu W, Nagpal S, Gephart MH, Quake SR. Brain tumor mutations detected in cerebral spinal fluid. Clin Chem. 2015;61(3):514–22.PubMedPubMedCentralCrossRef

126.

Li Y, Pan W, Connolly ID, Reddy S, Nagpal S, Quake S, et al. Tumor DNA in cerebral spinal fluid reflects clinical course in a patient with melanoma leptomeningeal brain metastases. J Neurooncol. 2016;128(1):93–100.PubMedPubMedCentralCrossRef

127.

De Mattos-Arruda L, Mayor R, Ng CK, Weigelt B, Martínez-Ricarte F, Torrejon D, et al. Cerebrospinal fluid-derived circulating tumour DNA better represents the genomic alterations of brain tumours than plasma. Nat Commun. 2015;6:8839.PubMedPubMedCentralCrossRef

128.

Momtaz P, Pentsova E, Abdel-Wahab O, Diamond E, Hyman D, Merghoub T, et al. Quantification of tumor-derived cell free DNA (cfDNA) by digital PCR (DigPCR) in cerebrospinal fluid of patients with BRAFV600 mutated malignancies. Oncotarget. 2016;7(51):85430–6.

129.

Dahmcke CM, Steven KE, Larsen LK, Poulsen AL, Abdul-Al A, Dahl C, et al. A prospective blinded evaluation of urine-DNA testing for detection of urothelial bladder carcinoma in patients with gross hematuria. Eur Urol. 2016;70(6):916–9.PubMedCrossRef

130.

Birkenkamp-Demtröder K, Nordentoft I, Christensen E, Høyer S, Reinert T, Vang S, et al. Genomic alterations in liquid biopsies from patients with bladder cancer. Eur Urol. 2016;70(1):75–82.PubMedCrossRef

131.

Armstrong DA, Green BB, Seigne JD, Schned AR, Marsit CJ. MicroRNA molecular profiling from matched tumor and bio-fluids in bladder cancer. Mol Cancer. 2015;14:194.PubMedPubMedCentralCrossRef

132.

Hyman DM, Diamond EL, Vibat CR, Hassaine L, Poole JC, Patel M, et al. Prospective blinded study of BRAFV600E mutation detection in cell-free DNA of patients with systemic histiocytic disorders. Cancer Discov. 2015;5(1):64–71.PubMedCrossRef

133.

Chen S, Zhao J, Cui L, Liu Y. Urinary circulating DNA detection for dynamic tracking of EGFR mutations for NSCLC patients treated with EGFR-TKIs. Clin Transl Oncol. 2017;19(3):332–40.

134.

Wang X, Meng Q, Wang C, Li F, Zhu Z, Liu S, et al. Investigation of transrenal KRAS mutation in late stage NSCLC patients correlates to disease progression. Biomarkers. 2016:1–7. doi:10.1080/1354750X.2016.1269202

135.

Chang HW, Tsui KH, Shen LC, Huang HW, Wang SN, Chang PL. Urinary cell-free DNA as a potential tumor marker for bladder cancer. Int J Biol Markers. 2007;22(4):287–94.PubMedCrossRef

136.

Zancan M, Galdi F, Di Tonno F, Mazzariol C, Orlando C, Malentacchi F, et al. Evaluation of cell-free DNA in urine as a marker for bladder cancer diagnosis. Int J Biol Markers. 2009;24(3):147–55.PubMedCrossRef

137.

Casadio V, Calistri D, Salvi S, Gunelli R, Carretta E, Amadori D, et al. Urine cell-free DNA integrity as a marker for early prostate cancer diagnosis: a pilot study. Biomed Res Int. 2013;2013:270457.PubMedPubMedCentralCrossRef

138.

Salvi S, Martignano F, Molinari C, Gurioli G, Calistri D, De Giorgi U, et al. The potential use of urine cell free DNA as a marker for cancer. Expert Rev Mol Diagn. 2016;16(12):1283–90.PubMedCrossRef

139.

Li N, Ma J, Guarnera MA, Fang H, Cai L, Jiang F. Digital PCR quantification of miRNAs in sputum for diagnosis of lung cancer. J Cancer Res Clin Oncol. 2014;140(1):145–50.PubMedCrossRef

140.

Izumchenko E, Chang X, Brait M, Fertig E, Kagohara LT, Bedi A, et al. Targeted sequencing reveals clonal genetic changes in the progression of early lung neoplasms and paired circulating DNA. Nat Commun. 2015;6:8258.PubMedPubMedCentralCrossRef

141.

Endrullat C, Glökler J, Franke P, Frohme M. Standardization and quality management in next-generation sequencing. Appl Transl Genomics. 2016;10:2–9.CrossRef

142.

Sato KA, Hachiya T, Iwaya T, Kume K, Matsuo T, Kawasaki K, et al. Individualized mutation detection in circulating tumor DNA for monitoring colorectal tumor burden using a cancer-associated gene sequencing panel. PLoS One. 2016;11(1):e0146275.PubMedPubMedCentralCrossRef

143.

Schmitt MW, Kennedy SR, Salk JJ, Fox EJ, Hiatt JB, Loeb LA. Detection of ultra-rare mutations by next-generation sequencing. Proc Natl Acad Sci USA. 2012;109(36):14508–13.PubMedPubMedCentralCrossRef

144.

Calvez-Kelm FL, Foll M, Wozniak MB, Delhomme TM, Durand G, Chopard P, et al. KRAS mutations in blood circulating cell-free DNA: a pancreatic cancer case-control. Oncotarget. 2016;7(48):78827–40.

145.

Newman AM, Lovejoy AF, Klass DM, Kurtz DM, Chabon JJ, Scherer F, et al. Integrated digital error suppression for improved detection of circulating tumor DNA. Nat Biotechnol. 2016;34(5):547–55.PubMedPubMedCentralCrossRef

146.

Kennedy SR, Schmitt MW, Fox EJ, Kohrn BF, Salk JJ, Ahn EH, et al. Detecting ultralow-frequency mutations by duplex sequencing. Nat Protoc. 2014;9(11):2586–606.PubMedPubMedCentralCrossRef

147.

Page K, Guttery DS, Fernandez-Garcia D, Hills A, Hastings RK, Luo J, et al. Next generation sequencing of circulating cell-free DNA for evaluating mutations and gene amplification in metastatic breast cancer. Clin Chem. 2017;63(2):532–41.

148.

Colling R, Wang LM, Soilleux E. Automated PCR detection of BRAF mutations in colorectal adenocarcinoma: a diagnostic test accuracy study. J Clin Pathol. 2016;69(5):398–402.PubMedCrossRef

149.

Wee EJ, Wang Y, Tsao SC, Trau M. Simple, sensitive and accurate multiplex detection of clinically important melanoma DNA mutations in circulating tumour DNA with SERS nanotags. Theranostics. 2016;6(10):1506–13.PubMedPubMedCentralCrossRef

150.

Takai E, Totoki Y, Nakamura H, Morizane C, Nara S, Hama N, et al. Clinical utility of circulating tumor DNA for molecular assessment in pancreatic cancer. Sci Rep. 2015;5:18425.PubMedPubMedCentralCrossRef

151.

Olmedillas López S, García-Olmo DC, García-Arranz M, Guadalajara H, Pastor C, García-Olmo D. KRAS G12V mutation detection by droplet digital PCR in circulating cell-free DNA of colorectal cancer patients. Int J Mol Sci. 2016;17(4):484.PubMedPubMedCentralCrossRef

Titel: Current and Emerging Applications of Droplet Digital PCR in Oncology
verfasst von: Susana Olmedillas-López
Mariano García-Arranz
Damián García-Olmo
Publikationsdatum: 01.10.2017
Verlag: Springer International Publishing
Erschienen in: Molecular Diagnosis & Therapy / Ausgabe 5/2017
Print ISSN: 1177-1062
Elektronische ISSN: 1179-2000
DOI: https://doi.org/10.1007/s40291-017-0278-8

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Mehr Lebenszeit mit Abemaciclib bei fortgeschrittenem Brustkrebs?

24.05.2024 Mammakarzinom Nachrichten

In der MONARCHE-3-Studie lebten Frauen mit fortgeschrittenem Hormonrezeptor-positivem, HER2-negativem Brustkrebs länger, wenn sie zusätzlich zu einem nicht steroidalen Aromatasehemmer mit Abemaciclib behandelt wurden; allerdings verfehlte der numerische Zugewinn die statistische Signifikanz.

ADT zur Radiatio nach Prostatektomie: Wenn, dann wohl länger

24.05.2024 Prostatakarzinom Nachrichten

Welchen Nutzen es trägt, wenn die Strahlentherapie nach radikaler Prostatektomie um eine Androgendeprivation ergänzt wird, hat die RADICALS-HD-Studie untersucht. Nun liegen die Ergebnisse vor. Sie sprechen für länger dauernden Hormonentzug.

„Überwältigende“ Evidenz für Tripeltherapie beim metastasierten Prostata-Ca.

22.05.2024 Prostatakarzinom Nachrichten

Patienten mit metastasiertem hormonsensitivem Prostatakarzinom sollten nicht mehr mit einer alleinigen Androgendeprivationstherapie (ADT) behandelt werden, mahnt ein US-Team nach Sichtung der aktuellen Datenlage. Mit einer Tripeltherapie haben die Betroffenen offenbar die besten Überlebenschancen.

So sicher sind Tattoos: Neue Daten zur Risikobewertung

22.05.2024 Melanom Nachrichten

Das größte medizinische Problem bei Tattoos bleiben allergische Reaktionen. Melanome werden dadurch offensichtlich nicht gefördert, die Farbpigmente könnten aber andere Tumoren begünstigen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Die Highlights vom Kongress des American College of Cardiology 2024

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 5/2017

Association of the miR-196a2, miR-146a, and miR-499 Polymorphisms with Asthma Phenotypes in a Korean Population

Is Next-Generation Sequencing the way to go for Residual Disease Monitoring in Acute Lymphoblastic Leukemia?

Early Diagnosis of Sepsis: Is an Integrated Omics Approach the Way Forward?

Identification and Characterization of a New BRCA2 Rearrangement in an Italian Family with Hereditary Breast and Ovarian Cancer Syndrome

The Role of Pharmacogenetics in Chronic Plaque Psoriasis: Update of the Literature